Brief: Krystal Biotech Announces EMA Validation Of Marketing Authorization Application For VYJUVEK
27/11/2023 12:17
Nov 27 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES EMA VALIDATION OF MARKETING
AUTHORIZATION APPLICATION FOR VYJUVEK FOR THE TREATMENT OF
DYSTROPHIC EPIDERMOLYSIS BULLOSA
* KRYSTAL BIOTECH INC - CHMP OPINION IS ANTICIPATED IN
SECOND HALF
OF 2024
Source text for Eikon: ID:nGNX4HpsL6
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion